BRIEF-Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.